Cardax devotes substantially all of
its efforts to developing and commercializing safe anti-inflammatory
dietary supplements and drugs. Cardax is initially focusing on
astaxanthin, which is a powerful and safe naturally occurring
anti-inflammatory without the side effects of currently marketed
anti-inflammatories. The safety and efficacy of Cardax's products have
not been directly evaluated in clinical trials or confirmed by the FDA.
Cardax Reports Q3 2017 Results
Revenues Up Nearly 5 Times from Q2 2017
HONOLULU, Nov. 14, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI)
announced strong ZanthoSyn® revenues of approximately $322,000 for the
third quarter of 2017 — up nearly 5 times from the second quarter of
2017, as reported in the Company's Form 10-Q filed today.
These results include the initial national stocking orders of ZanthoSyn
from General Nutrition Corporation ("GNC") for its more than 3,200
corporate stores across the US, as well as increased same-store sales
of ZanthoSyn in Hawaii GNC stores.
Management also highlighted the major milestones achieved this year
that have helped drive increasing sales:
ZanthoSyn national rollout to more than 3,200 GNC corporate stores in
Robust physician outreach and education in Hawaii
Increasing consumer awareness in Hawaii
Breakthrough anti-aging research results reported with research
collaborator University of Hawaii
Cardax astaxanthin compound CDX-085 chosen as top anti-aging prospect
Approximately $4 million in new capital raised to fund these efforts
"We are very pleased to see a strong trend of accelerating sales of
ZanthoSyn," said David G. Watumull, Cardax President and CEO. "We
believe it reflects our successful sales and marketing strategy focused
on increasing physician and consumer awareness of the anti-inflammatory
health benefits of ZanthoSyn. Additionally, the increased capital will
fuel further company growth and advance development of CDX-085, our
next generation ZanthoSyn product."
Please refer to the Form 10-Q filed by the Company today for additional
Cardax devotes substantially all of its efforts to developing and
commercializing safe anti-inflammatory dietary supplements and drugs.
Cardax is initially focusing on astaxanthin, which is a powerful and
safe naturally occurring anti-inflammatory without the side effects of
currently marketed anti-inflammatories. The safety and efficacy of
Cardax's products have not been directly evaluated in clinical trials
or confirmed by the FDA.
ZanthoSyn is a physician recommended anti-inflammatory supplement for
health and longevity that features astaxanthin with optimal absorption
and purity.* ZanthoSyn is sold online and in GNC stores. ZanthoSyn
contains astaxanthin, which is Generally Recognized as Safe (GRAS)
according to FDA regulations.
Astaxanthin is a clinically studied compound with safe
anti-inflammatory activity that supports joint health, cardiovascular
health, metabolic health, liver health, and longevity.*
Media and Investors
This release may contain certain forward-looking statements regarding
our prospective performance and strategies within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. We intend such
forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995, and are including this statement for
purposes of said safe harbor provisions. Forward-looking statements,
which are based on certain assumptions and describe future plans,
strategies, and expectations of our company, are generally identified
by use of words "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "project," "seek," "strive," "try," or future or
conditional verbs such as "could," "may," "should," "will," "would," or
similar expressions. Our ability to predict results or the actual
effects of our plans or strategies is inherently uncertain.
Accordingly, actual results may differ materially from anticipated
results. Some of the factors that could cause our actual results to
differ from our expectations or beliefs include, without limitation,
the risks discussed from time to time in our filings with the
Securities and Exchange Commission. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this release. Except as required by applicable law or
regulation, we undertake no obligation to update these forward-looking
statements to reflect events or circumstances that occur after the date
on which such statements were made.
* These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure,
or prevent any disease.
SOURCE Cardax, Inc.